Investigational drug · Phase 3
EYP-1901
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Macular Edema, DME, Diabetic Macular Edema (DME).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
8
Any phase or sponsor naming "EYP-1901"
First trial start
2024
Oct 22, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EYP-1901", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Macular Edema
- DME
- Diabetic Macular Edema (DME)
- Wet Age Related Macular Degeneration
- wAMD
Approved drugs for the same conditions: Wet macular degeneration · Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "EYP-1901" as an intervention, largest first.
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56Pivotal-lookingActive, not recruiting
EyePoint Pharmaceuticals, Inc.Industry
NCT06668064 · 400 participants (planned) · Start Oct 22, 2024 · Primary completion Jul 13, 2026
Drug: EYP-1901; Aflibercept (2.0 mg) · For: Wet Age Related Macular Degeneration; wAMD
Sites: Phoenix, Arizona; Springdale, Arkansas; Bakersfield, California · 76 sites in all
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Pivotal-lookingActive, not recruiting
EyePoint Pharmaceuticals, Inc.Industry
NCT06683742 · 400 participants (planned) · Start Nov 27, 2024 · Primary completion Sep 9, 2026
Drug: EYP-1901; Aflibercept (2.0 mg) · For: Wet Age Related Macular Degeneration; wAMD
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 113 sites in all
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPivotal-lookingActive, not recruiting
EyePoint Pharmaceuticals, Inc.Industry
NCT07449936 · 240 participants (planned) · Start Feb 16, 2026 · Primary completion Oct 2027
Drug: EYP-1901; Aflibercept (2.0 mg) · For: Diabetic Macular Edema; DME; Diabetic Macular Edema (DME)
Sites: Bakersfield, California; Encino, California; Glendale, California · 73 sites in all
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPivotal-lookingActive, not recruiting
EyePoint Pharmaceuticals, Inc.Industry
NCT07449923 · 240 participants (planned) · Start Feb 9, 2026 · Primary completion Oct 2027
Drug: EYP-1901; Aflibercept (2.0 mg) · For: Diabetic Macular Edema; DME; Diabetic Macular Edema (DME)
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 70 sites in all
- Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)Pivotal-lookingCompleted
EyePoint Pharmaceuticals, Inc.Industry
NCT05381948 · 161 participants · Start Jun 30, 2022 · Primary completion Nov 29, 2023
Drug: EYP-1901; Aflibercept 2mg/0.05mL Inj,Oph · For: Wet Age-related Macular Degeneration
Sites: Phoenix, Arizona; Springdale, Arkansas; Beverly Hills, California · 67 sites in all
EyePoint Pharmaceuticals, Inc.Industry
NCT05383209 · 77 participants · Start Sep 28, 2022 · Primary completion Feb 12, 2024
Drug: EYP-1901 · For: Nonproliferative Diabetic Retinopathy
Sites: Phoenix, Arizona; Huntington Beach, California; Oxnard, California · 36 sites in all
EyePoint Pharmaceuticals, Inc.Industry
NCT06099184 · 27 participants · Start Jan 15, 2024 · Primary completion Oct 24, 2024
Drug: EYP-1901; Aflibercept 2Mg/0.05Ml Inj,Oph · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Lemont, Illinois; Hagerstown, Maryland · 6 sites in all
EyePoint Pharmaceuticals, Inc.Industry
NCT04747197 · 17 participants · Start Jan 20, 2021 · Primary completion May 11, 2022
Drug: EYP-1901 · For: Wet Age-related Macular Degeneration
Sites: Phoenix, Arizona; Beverly Hills, California; Mountain View, California · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging solutions for neovascular age-related macular degeneration.
Franco JJ, Wubben TJ · Curr Opin Ophthalmol 2026
- Beyond the injection: delivery systems reshaping retinal disease management.
Rowe LW, Akotoye C, Harris A, et al. · Expert Opin Pharmacother 2025
- Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues.
Shirian JD, Shukla P, Singh RP · Eye (Lond) 2025
- Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration.
Patel S, Storey PP, Barakat MR, et al. · Ophthalmol Sci 2024
- Role of EYP-1901 in neovascular age-related macular degeneration and diabetic eye diseases: review of Phase I/II trials.
Sayed A, Ravichandran P, Canizela C, et al. · Ther Deliv 2024
- The evolving therapeutic landscape of diabetic retinopathy.
Shughoury A, Bhatwadekar A, Jusufbegovic D, et al. · Expert Opin Biol Ther 2023
Also in development for Diabetic Macular Edema
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- OCS-01Phase 32 trials
Oculis · Diabetic Macular Edema
- AVT29proposed aflibercept HD biosimilarPhase 31 trial
Alvotech Swiss AG · Diabetic Macular Edema
- Intravitreal RanibizumabPhase 31 trial
Roche (Genentech) · Diabetic Macular Edema
- BI 3812465Phase 21 trial
Boehringer Ingelheim · Diabetic Macular Edema
- CU06-1004Phase 21 trial
Curacle Co., Ltd. · DME, Diabetic Macular Edema, Diabetic Macular Edema (DME)
- OXU-001DEXAspheresPhase 21 trial
Oxular Limited · Diabetic Macular Edema
- RO7446603Phase 21 trial
Roche (Genentech) · Diabetic Macular Edema
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.